ProQR Therapeutics
PRQR
65 hedge funds and large institutions have $75.1M invested in ProQR Therapeutics in 2025 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 10 reducing their positions, and 8 closing their positions.
130% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 10
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
2% more funds holding
Funds holding: 64 → 65 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.37% less ownership
Funds ownership: 35.68% → 35.31% (-0.37%)
6% less capital invested
Capital invested by funds: $80M → $75.1M (-$4.91M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.64M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$1.52M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.4M |
| 4 |
Two Sigma Investments
New York
|
+$986K |
| 5 |
PFM
Privium Fund Management
Amsterdam,
Netherlands
|
+$840K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.59M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$3.31M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$2.68M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$1.32M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$196K |
PRQR Hedge Fund Activity: Q4 2025 in Review
65 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2025, worth a combined $75.1M — down 6.1% from $80M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new PRQR positions and 8 closed out — a net gain of 2 holders — while 23 added to existing stakes and 10 trimmed.
The largest buyer was UBS Group, adding an estimated $1.64M. The largest seller was Morgan Stanley, cutting an estimated $3.59M.
- 65 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2025, up from 64 in Q3 2025.
- Funds reported $75.1M of ProQR Therapeutics stock for Q4 2025, down 6.1% quarter-over-quarter.
- 10 funds opened new ProQR Therapeutics positions in Q4 2025 and 8 closed out, a net change of +2 holders.
- The largest ProQR Therapeutics buyer in Q4 2025 was UBS Group, an estimated $1.64M added.
- The largest ProQR Therapeutics seller in Q4 2025 was Morgan Stanley, an estimated $3.59M sold.
Based on aggregated 13F filings for Q4 2025.